Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Ltd

₹ 389 -0.18%
28 Mar - close price
About

Kilitch Drugs (India) Ltd is a speciality pharmaceutical company engaged in manufacturing and trading of pharmaceutical products in domestic and international markets.[1]

Key Points

Product Portfolio
The company's product portfolio includes parenteral and nasal products, oral formulations, effervescent tablets & powders, medical devices, nutritional products, cosmetics & herbal products & others. Besides this, it has 400+ products registered across the world. [1] [2]

  • Market Cap 625 Cr.
  • Current Price 389
  • High / Low 470 / 138
  • Stock P/E 50.3
  • Book Value 104
  • Dividend Yield 0.00 %
  • ROCE 9.88 %
  • ROE 5.40 %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 3.74 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 4.03% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
20.33 19.93 19.62 23.57 34.43 36.61 33.45 30.70 29.97 45.48 36.56 41.20 31.79
17.31 19.61 18.71 19.92 33.66 31.57 30.03 26.75 25.99 39.26 30.38 32.58 29.51
Operating Profit 3.02 0.32 0.91 3.65 0.77 5.04 3.42 3.95 3.98 6.22 6.18 8.62 2.28
OPM % 14.85% 1.61% 4.64% 15.49% 2.24% 13.77% 10.22% 12.87% 13.28% 13.68% 16.90% 20.92% 7.17%
0.37 1.51 1.05 0.17 1.31 0.38 0.97 0.24 0.69 1.02 0.56 0.49 2.96
Interest 0.12 0.16 0.13 0.12 0.24 0.71 0.67 1.75 1.29 1.21 1.50 1.51 1.60
Depreciation 0.50 0.50 0.44 0.70 0.20 1.13 0.82 0.89 0.93 0.91 0.71 0.82 0.81
Profit before tax 2.77 1.17 1.39 3.00 1.64 3.58 2.90 1.55 2.45 5.12 4.53 6.78 2.83
Tax % 21.30% 40.17% 47.48% 14.00% 62.80% 36.03% 40.00% -25.16% 30.61% 43.16% 32.67% 24.93% 38.16%
2.18 0.71 0.72 2.58 0.61 2.30 1.74 1.94 1.71 2.90 3.06 5.09 1.74
EPS in Rs 1.43 0.46 0.76 1.39 0.72 1.86 1.34 1.56 1.52 2.28 2.16 2.95 1.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
143 146 108 19 21 27 51 82 53 68 114 140 155
119 124 95 21 25 28 45 75 53 63 104 122 132
Operating Profit 23 22 13 -2 -4 -1 6 7 0 5 10 18 23
OPM % 16% 15% 12% -9% -19% -2% 11% 9% 1% 8% 9% 13% 15%
0 0 92 3 2 1 3 4 4 3 3 3 5
Interest 5 4 3 0 0 0 0 1 1 1 1 5 6
Depreciation 6 6 5 2 10 10 2 2 2 2 2 4 3
Profit before tax 13 13 97 -1 -12 -9 6 9 2 5 10 12 19
Tax % 22% 20% 22% 70% 4% 5% 16% 55% 48% 27% 35% 31%
10 10 76 -0 -11 -9 5 4 1 4 6 8 13
EPS in Rs 7.75 7.93 57.67 -0.22 -8.46 -6.72 3.75 2.49 0.54 2.43 4.73 6.71 9.20
Dividend Payout % 13% 13% 52% 0% 0% 0% 13% 20% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 22%
3 Years: 38%
TTM: 19%
Compounded Profit Growth
10 Years: %
5 Years: 12%
3 Years: 237%
TTM: 62%
Stock Price CAGR
10 Years: 35%
5 Years: 15%
3 Years: 68%
1 Year: 177%
Return on Equity
10 Years: %
5 Years: 3%
3 Years: 4%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 13 13 13 13 13 13 14 15 15 15 16 16 16
Reserves 62 71 101 107 95 88 98 106 103 112 121 131 151
43 16 9 0 0 1 1 9 13 15 20 22 29
21 53 54 7 8 11 15 13 12 61 53 51 41
Total Liabilities 139 153 177 127 117 113 128 144 143 203 210 220 237
44 42 9 9 42 33 33 32 32 30 65 64 64
CWIP 22 43 0 0 0 1 3 20 30 65 3 4 3
Investments 1 0 138 72 49 53 56 53 52 60 71 62 66
72 68 30 46 25 26 35 38 30 47 71 90 104
Total Assets 139 153 177 127 117 113 128 144 143 203 210 220 237

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
12 22 -29 -8 17 1 1 0 4 46 6 3
-20 -24 41 -31 -20 -2 -4 -14 -10 -38 -15 8
7 7 -9 -0 0 -0 6 17 1 2 7 -1
Net Cash Flow -1 6 2 -39 -2 -0 2 3 -5 10 -2 10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 123 97 51 243 286 196 148 86 109 122 132 142
Inventory Days 46 62 12 124 110 84 39 36 70 35 28 10
Days Payable 44 37 19 124 154 184 108 33 89 525 239 200
Cash Conversion Cycle 125 121 44 243 241 96 79 89 89 -367 -79 -48
Working Capital Days 107 19 -114 197 237 124 100 79 108 -144 25 54
ROCE % 15% 8% -10% -9% 5% 6% 1% 3% 6% 10%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
68.63% 68.33% 68.33% 68.25% 68.25% 68.25% 68.24% 68.24% 68.24% 68.24% 69.23% 69.23%
0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
31.37% 31.67% 31.67% 31.73% 31.75% 31.75% 31.75% 31.75% 31.75% 31.76% 30.78% 30.76%
No. of Shareholders 9,7569,2148,7409,1299,1339,2099,3809,4359,5229,5739,0029,062

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents